| A Trial of CRD-4730 in HFrEF (NCT07750873) | Cardurion Pharmaceuticals, Inc. | 2026-07-15 |
| A Phase 2 Study of CRD-4730 in CPVT (NCT06658899) | Cardurion Pharmaceuticals, Inc. | 2025-12-01 |
| A Study to Assess Safety & Effectiveness of Tovinontrine in Chronic Heart Failure With Reduced Ejection Fraction (Cycle-1-REF) (NCT06215911) | Cardurion Pharmaceuticals, Inc. | 2024-02-13 |
| Safety & Effectiveness of Tovinontrine in Chronic Heart Failure With Preserved Ejection Fraction (Cycle-2-PEF) (NCT06215586) | Cardurion Pharmaceuticals, Inc. | 2024-02-13 |
| Effectiveness of CRD-4730 in Participants With Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) (NCT06005428) | Cardurion Pharmaceuticals, Inc. | 2023-11-07 |
| Effect of Coadministration of Itraconazole on the Pharmacokinetics of CRD-740 (NCT05437094) | Cardurion Pharmaceuticals, Inc. | 2022-06-27 |
| Effectiveness of CRD-740 in Heart Failure (NCT05409183) | Cardurion Pharmaceuticals, Inc. | 2022-05-26 |
| Selective PDE9 Inhibition With IMR-687 in Adults With Heart Failure With Preserved Ejection Fraction (NCT05312021) | Cardurion Pharmaceuticals, Inc. | 2022-04-01 |
| A Study of IMR-687 in Subjects With Beta Thalassemia (NCT04411082) | Cardurion Pharmaceuticals, Inc. | 2020-10-16 |
| A Study of IMR-687 in Subjects With Sickle Cell Disease (NCT04474314) | Cardurion Pharmaceuticals, Inc. | 2020-08-13 |
| A Study of IMR-687 in Adult Participants With Sickle Cell Anemia (Homozygous HbSS or Sickle-β0 Thalassemia) (NCT03401112) | Cardurion Pharmaceuticals, Inc. | 2018-01-26 |